The study was successful in inhibiting the Aβ-TMEM97 interaction with the APP/PS1+Tau mouse model of AD; this was achieved by using CT1812 (n = 20); the drug concentration was negatively associated with synaptic Förster resonance energy transfer (FRET) signals between Aβ and TMEM97 [45]. This evidence concerns the gene MAPT and Alzheimer disease.